Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) Non Operating Income (2019 - 2025)

Revolution Medicines has reported Non Operating Income over the past 7 years, most recently at $51.1 million for Q4 2025.

  • Quarterly results put Non Operating Income at $51.1 million for Q4 2025, down 43.95% from a year ago — trailing twelve months through Dec 2025 was $68.0 million (down 48.16% YoY), and the annual figure for FY2025 was $51.1 million, down 42.41%.
  • Non Operating Income for Q4 2025 was $51.1 million at Revolution Medicines, up from $16.9 million in the prior quarter.
  • Over the last five years, Non Operating Income for RVMD hit a ceiling of $91.2 million in Q4 2024 and a floor of -$2.8 million in Q1 2024.
  • Median Non Operating Income over the past 5 years was $5.1 million (2022), compared with a mean of $13.5 million.
  • Biggest five-year swings in Non Operating Income: skyrocketed 2237.42% in 2023 and later plummeted 139.79% in 2024.
  • Revolution Medicines' Non Operating Income stood at $237000.0 in 2021, then soared by 2042.19% to $5.1 million in 2022, then soared by 270.08% to $18.8 million in 2023, then skyrocketed by 385.33% to $91.2 million in 2024, then plummeted by 43.95% to $51.1 million in 2025.
  • The last three reported values for Non Operating Income were $51.1 million (Q4 2025), $16.9 million (Q2 2025), and -$10000.0 (Q1 2025) per Business Quant data.